The global ATP Assays market is projected to reach USD 0.5 billion by 2028 from USD 0.3 billion in 2023, at a CAGR of 7.8% during the forecast period. Growth in this market is majorly driven by the growing food safety concerns, increasing demand for ATP assays in pharmaceutical & biotechnology companies, and growing investments in pharmaceutical & biotechnology R&D. However, high equipment prices are expected to restrain market growth to a certain extent.
The prominent players in ATP assays market are Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Merck KGaA (Germany), PerkinElmer, Inc. (US), Agilent Technologies, Inc. (US), Abcam plc (UK), Lonza Group (Switzerland), Neogen Corporation (US), Abnova Corporation (Taiwan), AAT Bioquest,Inc. (US), BioThema AB (Sweden), Elabscience Biotechnology Inc. (US), MBL International Corporation (US), Biotium (US), Creative Bioarray (US), Canvax Biotech S.L. (Spain), Ruhof Corporation (US), Charm Sciences, Inc. (US), Bio Shield Tech, LLC (US), Cayman Chemical (US), and Cell Signaling Technology,Inc. (US).
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific, Inc. (US) held the first position in the ATP Assays market in 2022. The company offers scientific instrumentation products, reagents and consumables, and software & services to the healthcare, life science, academic, government, and biotechnology & pharmaceutical sectors. It provides ATP reagents & kits through its Life Science Solutions segment and provides instruments for the ATP assays market through its Analytical Instruments segment. The company has a strong geographic footprint serving more than 400,000 customers across a wide range of pharmaceutical and biotechnology companies, hospitals and clinical diagnostic labs, universities, research institutes and government agencies, as well as environmental, industrial quality, and process control settings. In 2021, sales in the Life Sciences Solutions and Analytical Instruments segments increased to USD 21.70 billion from USD 17.29 billion in 2020. Further, the company has increased its R&D capabilities to maintain a competitive advantage. In 2021, the company invested USD 1.41 billion in the research & development of new products to cater to the unmet needs in the healthcare industry. This increasing R&D helped the company to launch new products in this market. In May 2020, Thermo Fisher launched the Orbitrap 240 Mass Spectrometer. It is designed to give proteomics, metabolomics, and biopharmaceutical characterization to small molecules, which aids in research and high-throughput analyses.
Merck KGaA (Germany) operates through three business segments, namely, Healthcare, Life Science, and Performance Materials. The Life Science business segment consists of the Merck Millipore business and the acquired life science business of Sigma-Aldrich Corporation (US). Merck provides ATP kits, reagents, and instruments through its Life Science segment. This segment offers a broad portfolio of products and services for customers across the globe. Merck provides ATP assay reagents and kits that are manufactured by Roche Diagnostics as part of its product portfolio under Sigma-Aldrich Corporation (US). The company has a strong geographical presence in 66 countries across the Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa. Merck invests substantially in R&D to provide innovative products. In 2022, the company invested USD 2.66 billion in R&D. With its strong R&D capabilities and geographical presence, the company is expected to maintain its leading position in the market. The company focuses on in-house research and external partnerships in its R&D operations, maximizing its research efficiency while reducing financial outlays. In the Life Science business sector, Merck invested in research, development, and production in FY 2022.
PerkinElmer, Inc. (US) is a leading provider of products, services, and solutions to the diagnostics, life sciences, and applied markets. It provides detection, imaging, services, and informatics. The company’s customer base includes pharmaceutical and biotechnology companies and academic research institutes. PerkinElmer has two business segments, namely, Discovery & Analytical Solutions and Diagnostics. PerkinElmer provides ATP assays in the market through its Discovery & Analytical Solutions segment. The company has 20 offices in the US, China, Japan, the UK, Germany, France, and Italy. The company has a diversified product portfolio, and its position in the market is attributed to its active acquisitions for the adoption of advanced technologies. In 2021, it acquired Nexcelom Bioscience (US) to help scientists resolve some of today’s most pressing health challenges through modernizing cell-based assays using the most advanced cell models. Through this acquisition, the company will bring Nexcelom’s expertise and technologies in drug development together with the passion and solutions for drug discovery.
ATP Assays Market by Product (Consumables (Reagents, Microplate), Instruments (Luminometer, Spectrophotometer)), Application (Contamination, Disease Testing, Drug Discovery), End User (Hospitals, Pharmaceuticals, F&B, Academics) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE